There are several studies based on different imaging methods aiming to support that PCSK9 inhibitors reduce arterial wall inflammation and atherosclerosis burden by modifying atherosclerotic plaque characteristics [138,139,140,141,142,143,144,145]. Here, PCSK9 is linked to atherosclerosis.